Freenome, Inc. FRNM

Healthcare SIC 8071 - Services-Medical Laboratories Nasdaq

We are a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company formed for the purpose of effecting a business combination with one or more businesses, which we refer to throughout this Annual Report as our initial business combination. To date, our efforts have been limited to organizational activities, as activities related to our Initial Public Offering, and since our Initial Public Offering, the search for a prospective business combination. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination.

While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team's background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries. In particular, we are targeting North American or European companies in the life sciences and medical technology sectors where our management has extensive investment experience. We may pursue a transaction in which our shareholders immediately prior to the completion of our initial business combination would collectively own a minority interest in the post-business combination company.

Last close 16.31 2026-09-04
Market cap $145.3M 2025-12-31 share count
52-week range 9.97 - 17.18

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
SG&A $3.0M
Operating income -$3.0M
Net income $837.5K

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $865.0K$1.1M$0
Total current assets $907.6K$1.2M
Total assets $92.8M$89.9M
Total current liabilities $2.3M$210.8K
Total liabilities $5.7M$3.7M
Retained earnings -$4.8M-$2.1M
Total equity -$4.8M-$2.1M$0

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$864.7K
Stock-based compensation $0
Investing cash flow $600.0K
Financing cash flow $0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-033585.

Others in SIC 8071

TickerCompanyMarket capP/ERevenue growth
NTRA Natera, Inc. $47.31B 35.9%
LH LABCORP HOLDINGS INC. $26.51B 31.3x 7.2%
DGX QUEST DIAGNOSTICS INC $26.17B 27.1x 11.8%
GH Guardant Health, Inc. $21.66B 32.9%
CAI Caris Life Sciences, Inc. $7.08B 97.0%
RDNT RadNet, Inc. $5.80B 11.5%
CELC Celcuity Inc. $4.68B
BLLN BillionToOne, Inc. $4.61B 709.9x 100.0%